ADIL FY2025 EPS Raised by Litchfield Hills Research

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) – Analysts at Litchfield Hills Research upped their FY2025 earnings estimates for Adial Pharmaceuticals in a research report issued on Thursday, February 12th. Litchfield Hills Research analyst T. O’neill now anticipates that the company will post earnings of ($7.92) per share for the year, up from their prior estimate of ($12.00). The consensus estimate for Adial Pharmaceuticals’ current full-year earnings is ($1.53) per share. Litchfield Hills Research also issued estimates for Adial Pharmaceuticals’ Q4 2025 earnings at ($1.94) EPS, Q1 2026 earnings at ($1.77) EPS, Q2 2026 earnings at ($1.86) EPS, Q3 2026 earnings at ($1.95) EPS, Q4 2026 earnings at ($1.95) EPS and FY2026 earnings at ($7.55) EPS.

A number of other analysts have also issued reports on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Adial Pharmaceuticals in a research report on Wednesday, January 21st. UBS Group set a $8.00 price target on shares of Adial Pharmaceuticals in a research note on Wednesday, February 11th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Adial Pharmaceuticals has an average rating of “Hold” and an average price target of $22.75.

Adial Pharmaceuticals Price Performance

Shares of ADIL stock opened at $2.70 on Monday. The company’s fifty day moving average price is $5.39 and its two-hundred day moving average price is $7.65. The firm has a market capitalization of $3.00 million, a P/E ratio of -0.14 and a beta of 1.26. Adial Pharmaceuticals has a 12 month low of $2.59 and a 12 month high of $32.50.

Institutional Investors Weigh In On Adial Pharmaceuticals

A hedge fund recently bought a new stake in Adial Pharmaceuticals stock. Citadel Advisors LLC acquired a new position in shares of Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 143,791 shares of the company’s stock, valued at approximately $51,000. Citadel Advisors LLC owned 0.60% of Adial Pharmaceuticals at the end of the most recent quarter. 16.41% of the stock is owned by institutional investors.

Adial Pharmaceuticals Company Profile

Adial Pharmaceuticals, Inc, incorporated in Delaware and founded in 2003, is a clinical-stage specialty pharmaceutical company dedicated to the development of treatments for addiction disorders and central nervous system conditions. The company’s mission centers on creating novel modalities designed to enhance patient adherence and clinical outcomes, particularly in areas of high unmet medical need. Adial leverages sustained-release delivery technologies to address the challenges associated with oral medication regimens in addiction therapy.

The company’s lead product candidate, AD04, is a bioerodible subcutaneous implant engineered to deliver naltrexone continuously over a multi-month period for individuals with alcohol dependence.